Patient Portal

Charles F. Zorumski, MD

Samuel B. Guze Professor and Head of Psychiatry
Professor of Neurobiology

Specialty Areas

Adult Psychiatry

Board Certifications


Hospital Affiliations

Barnes-Jewish Hospital

Referral Information

Not Accepting New Patients

Areas of Clinical Interest

Electroconvulsive therapy, brain stimulation methods, electrophysiology, exitotoxic neuronal damage and neuropsychiatric disorders

  • Location(s)
  • Education
  • Publication & Research
  • Financial Disclosures



Barnes-Jewish Hospital (South)
Renard Hospital Building

4940 Children's Place
St. Louis, MO 63110

Suite: Room 2208
Office Phone: 314-747-2680
Fax: 314-747-2682



Residency: Washington University School of Medicine, St. Louis, Missouri 1982
Medical Degree: St. Louis University, St. Louis, Missouri 1978
Bachelor of Art: St. Louis University, St. Louis, Missouri 1974

Publication & Research

Publication & Research

Paul SM, Doherty JJ, Robichaud AJ, Belfort GM, Chow BY, Hammond RS, Crawford DC, Linsenbardt AJ, Shu HJ, Izumi Y, Mennerick SJ, Zorumski CF (2013 Oct 30). The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. J Neurosci. 33(44): 17290-300.  

Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S (2013 Jan). Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev. 37(1): 109-22.  

Izumi Y, Zorumski CF (2014 Nov). Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function. Neuropharmacology. 86273-81.  

Sun M-Y,Izumi Y,Benz A, Zorumski CF, Mennerick S, (2015 Dec) Endogenous 24S-hydroxycholesterol modulates NMDAR-mediated function in hippocampal slices. J Neurophysiology 23;115:1263-72;  

Zorumski CF,Nagele P, Mennerick S, Conway CR Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy. Frontiers in Psychiatry 2015; 6:172  

Zorumski CF, Izumi Y, Mennerick S: Ketamine: NMDA receptors and beyond. Journal of Neuroscience 2016; 36: 11158-11166.   

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2019:

Company Name: Sage Therapeutics, Inc.


Equity: Yes

Consulting/Advisory Board: $20,000 - $39,999

Speaker Fees:

Reporting Date: May 01, 2020